MedtechLedger currently links 76 FDA records to the applicant name Boston Scientific. The collection includes 4 510(k) clearances. It includes 2 original PMA approvals. 30 entries are PMA supplements. 40 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 26, 1993 to Oct 3, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LWS appears in 33 of the 76 linked filings. The collection spans 8 FDA product codes and 9 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P150012, with 23 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 4 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 4100 Hamline Ave. N, St Paul, MN, 55112. Recorded on P150012/S191, decision dated Oct 3, 2026.
Device categories in this collection
Implantable Pulse Generator, Pacemaker (Non-Crt); Implantable Cardioverter Defibrillator (Non-Crt); Unit, Electrosurgical, Endoscopic (With Or Without Accessories); Computer, Diagnostic, Programmable; Mesh, Surgical; Drug Eluting Permanent Right Ventricular (Rv) Or Right Atrial (Ra) Pacemaker Electrodes.
The FDA record P150012/S191 lists Boston Scientific as applicant for a 30-Day Notice supplement to PMA P150012, decided OK30 on 2026-10-03. The reported statement describes two manufacturing-related actions: implementing an additional acceptance activity for Accolade SL batteries and changing a specification for an existing Accolade EL battery specification. The device category is implantable pulse generator, pacemaker (non-CRT), product code LWP.
The action concerns battery acceptance and specification items, not a new approval of the whole system. The record does not identify which acceptance activity was added, what the revised EL specification is, or what validation data supported either change, so those details remain absent and the statement's purpose is not evidence of safety or clinical effectiveness.
FDA approval-order wording
to implement an additional acceptance activity for Accolade SL batteries and to change a specification for an existing Accolade EL battery specification
FDA’s recorded scope: approval for supplemental labeling for the ENDOTAK RELIANCE ePTFE family of defibrillator leads to align with a July 2025 Product Advisory.
FDA’s recorded scope: approval for the SMR16 software maintenance release to update the NG4 pulse generator firmware and Model 3868 Tachy programmer software application
FDA’s recorded scope: to add a functionally equivalent alternate vapor degreasing solvent used to remove contaminants from pulse generator components
Jul 23, 2026 · 30-Day Notice
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.